What is intravascular large B-cell lymphoma?
Intravascular large B-cell lymphoma (IVLBCL) is an uncommon, fast-moving form of non-Hodgkin lymphoma. What makes it unusual is where the cancer cells live: instead of forming lumps in lymph nodes, the lymphoma cells grow inside the smallest blood vessels, such as capillaries, throughout the body.
Because there is usually no visible tumour or enlarged lymph node, IVLBCL is one of the most difficult cancers to diagnose. It often shows up as unexplained fever, confusion or stroke-like episodes, skin changes or abnormal blood tests, and it has been called “a chameleon with many masks” (Ponzoni, Campo and Nakamura, 2018).
The disease mainly affects older adults, with an average age around 70. Without treatment it progresses quickly, and in the past many cases were only discovered after death. Today, with earlier diagnosis using skin and bone marrow biopsies and treatment with R-CHOP chemotherapy combined with treatment aimed at the brain, most people respond well and many remain in remission for years (Shimada et al., 2025).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Aggressive B-cell non-Hodgkin lymphoma inside small blood vessels |
| How common | Rare; well under 1 case per million people per year in most countries |
| Typical age | Older adults; median about 70 |
| Sex | Men and women affected about equally; the skin-only form is more common in women |
| Common sites | Brain, skin, bone marrow, lungs, kidneys, adrenal glands, liver and spleen |
| Main clues | Fever, confusion, skin patches, low blood counts, very high LDH |
| Key test | Random deep skin biopsy and bone marrow biopsy |
| Main treatment | R-CHOP plus high-dose methotrexate and spinal fluid chemotherapy |
| Outlook | Much improved; about 3 in 4 alive at 5 years in a recent trial |
2. Types of IVLBCL
| Type | Main features | Notes |
|---|---|---|
| Classic type | Brain and skin symptoms, fever | More often described in Western countries |
| Haemophagocytic syndrome-associated type | Fever, low blood counts, big liver and spleen, bone marrow involvement | More often described in East Asia; formerly called the “Asian variant” |
| Cutaneous (skin-only) type | Disease limited to the skin | Mainly women; better outlook (Breakell et al., 2022) |
3. Causes and risk factors
The cause of IVLBCL is not known. It is not infectious and is not inherited.
| Factor | Notes |
|---|---|
| Older age | Most patients are over 60 |
| Weakened immune system | Occasionally reported, but most patients have no immune problem |
| Gene changes in the tumour | MYD88 and CD79B mutations are common, similar to some other extranodal lymphomas |
Why do the cells stay inside vessels?
Researchers believe the lymphoma cells lack certain “homing” molecules that normally let white blood cells leave the bloodstream and enter tissues. As a result, they become trapped inside small vessels, where they block blood flow and cause damage to the organs supplied (Shimada and Kiyoi, 2021).
4. How does it look
On the skin
About 1 in 4 to 1 in 3 people have skin involvement, though the skin can be affected even when it looks normal.
| Feature | Description |
|---|---|
| Patches | Red, purple or bruise-like areas |
| Plaques and lumps | Firm, slightly raised areas, sometimes painful |
| Blood vessels | Visible small vessels (telangiectasia) |
| Swelling | Puffy, firm skin, often on the thighs or tummy |
| Common sites | Thighs, abdomen, breasts, arms |
On scans
Standard CT scans often look normal or show only subtle changes. Clues may include:
| Scan | Possible findings |
|---|---|
| Brain MRI | Small areas of damage resembling strokes, or patchy white-matter changes |
| CT chest | Hazy shadows in the lungs |
| PET-CT | Increased activity in the bone marrow, spleen, adrenal glands, lungs or kidneys |
| Ultrasound | Enlarged liver or spleen |
Under the microscope
| Feature | Description |
|---|---|
| Location | Large lymphoma cells filling the inside of small vessels, with little or no tumour outside them |
| Cells | Large B cells with prominent nucleoli and many mitoses |
| Markers | CD20 and CD79a positive; often MUM1 positive and CD10 negative |
| Highlight stain | CD34 or other vessel stains show the cells lie within vessel walls |
| Skin biopsy | Cells often found in the small vessels of the fat layer |
5. Symptoms
Symptoms depend on which organs’ small vessels are blocked. They are often vague and varied, which is why the diagnosis is frequently delayed.
General symptoms
- Fever without an obvious cause, often lasting weeks
- Night sweats and weight loss
- Severe tiredness
- Loss of appetite
Symptoms by organ
| Organ | Possible symptoms |
|---|---|
| Brain | Confusion, memory loss, rapidly worsening dementia, stroke-like weakness, seizures, unsteadiness |
| Spinal cord and nerves | Leg weakness, numbness, bladder problems |
| Skin | Painful red or purple patches and firm swelling |
| Lungs | Breathlessness, low oxygen levels, cough |
| Bone marrow | Anaemia, bleeding, infections |
| Adrenal glands | Low blood pressure, weakness, salt imbalance |
| Kidneys | Protein in the urine, kidney failure |
| Liver and spleen | Abdominal swelling, jaundice |
Blood test clues
| Test | Typical finding |
|---|---|
| LDH | Very high |
| Soluble IL-2 receptor | Very high |
| Blood counts | Anaemia, low platelets |
| Ferritin | High, especially with haemophagocytic syndrome |
| Inflammation markers | Raised CRP and ESR |
When to seek medical advice
See a doctor about fever lasting more than a week or two without an obvious cause, unexplained weight loss, or new memory problems or confusion. Seek emergency care for sudden weakness, difficulty speaking, a seizure or severe breathlessness.
6. Diagnosis
IVLBCL is often considered only after many other tests have been normal. Doctors suspect it in people with unexplained fever, neurological symptoms and very high LDH.
| Test | Purpose |
|---|---|
| Random skin biopsy | Several deep biopsies of normal-looking skin, including fat, often from the thighs and abdomen; a key test |
| Biopsy of abnormal skin | If patches or lumps are present |
| Bone marrow biopsy | Frequently shows lymphoma cells |
| PET-CT | Shows areas of hidden disease and guides biopsy |
| Brain MRI and lumbar puncture | Checks for brain and spinal fluid involvement |
| Biopsy of other organs | Such as the adrenal gland, lung or kidney when abnormal on scans |
| Blood tests | LDH, sIL-2R, ferritin, kidney and liver function |
Random skin biopsy explained
| Step | What happens |
|---|---|
| 1. Choosing sites | Usually 3 or more areas of normal-looking skin with fatty tissue, such as the thighs and lower abdomen |
| 2. Local anaesthetic | The skin is numbed with a small injection |
| 3. Biopsy | A small, deep piece of skin and fat is removed, usually with a punch or small incision |
| 4. Closing | One or two stitches; a dressing is applied |
| 5. Results | Pathologists look for lymphoma cells inside small vessels, usually within a few days |
The procedure is quick and done at the bedside or in clinic, and it can make the diagnosis without the need for more invasive surgery.
Conditions that can look similar
| Condition | Notes |
|---|---|
| Infections | Such as tuberculosis or endocarditis, causing fever of unknown origin |
| Vasculitis | Inflammation of blood vessels, which can also cause brain and skin problems |
| Strokes from other causes | Similar MRI appearance |
| Other causes of haemophagocytic syndrome | Including other lymphomas and infections |
7. Treatment
Treatment is given by a lymphoma team and should start as soon as possible, because the disease progresses quickly.
First treatment
| Treatment | Notes |
|---|---|
| R-CHOP | Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone, usually 6 cycles |
| High-dose methotrexate | Given between or after R-CHOP cycles to protect the brain |
| Intrathecal chemotherapy | Drugs injected into the spinal fluid |
| Supportive care | Transfusions, antibiotics, treatment of low blood pressure or adrenal failure |
In the Japanese PRIMEUR-IVL trial, 37 patients without brain involvement at diagnosis received this combined approach. After about 7 years of follow-up, 68% remained free of progression and 78% were alive at 5 years, and the lymphoma rarely spread to the brain (Shimada et al., 2025).
If the brain is involved at diagnosis
Treatment follows approaches used for primary brain lymphoma, with higher doses of drugs that reach the brain, such as methotrexate and cytarabine, sometimes followed by high-dose chemotherapy with stem cell rescue in fit patients.
Relapsed disease
| Option | Notes |
|---|---|
| Second-line chemotherapy | Platinum or other combinations |
| Stem cell transplant | For fit patients who respond |
| CAR T-cell therapy and bispecific antibodies | Used for relapsed large B-cell lymphomas and increasingly considered in IVLBCL |
| BTK inhibitors | Such as ibrutinib, being studied, especially with brain involvement |
| Clinical trials | Encouraged where available |
Side effects
| Treatment | Possible side effects |
|---|---|
| R-CHOP | Hair loss, sickness, infections, tingling in hands and feet, constipation, tiredness |
| High-dose methotrexate | Kidney and liver effects, mouth sores; needs hospital stay and monitoring |
| Intrathecal chemotherapy | Headache, back pain |
| Steroids | High blood sugar, mood changes, sleep problems |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| R-CHOP | Day-unit treatment every 3 weeks for about 4-5 months |
| High-dose methotrexate | Hospital stay of 2-4 days per course |
| Lumbar punctures | Short procedures for spinal fluid chemotherapy |
| Blood tests | Before each cycle and in between |
8. Outlook (prognosis)
| Situation | Approximate outlook |
|---|---|
| Before rituximab | Poor; many patients died within a year |
| R-CHOP-based treatment | Large improvement; most respond |
| R-CHOP plus CNS-directed treatment (PRIMEUR-IVL) | About 78% alive and 68% progression-free at 5 years |
| Cutaneous type | Usually better than other types |
| Brain involvement or haemophagocytic syndrome | Generally more difficult to treat |
Older age, poor fitness, brain involvement and delayed diagnosis are linked with a poorer outlook. Prompt diagnosis is the single most important step (Davis et al., 2022).
9. Follow-up
| Follow-up | Purpose |
|---|---|
| Clinic visits every 3 months for 2 years | Check symptoms and examine the skin and nervous system |
| Blood tests | LDH, sIL-2R and blood counts can signal relapse |
| PET-CT | After treatment to confirm remission, and if relapse is suspected |
| Brain MRI | If new neurological symptoms appear |
| Late effect monitoring | Heart function after doxorubicin, nerve damage, second cancers |
10. Living with intravascular large B-cell lymphoma
- Report fevers immediately during chemotherapy, as infections can be serious
- Ask about memory and rehabilitation support if the brain was affected
- Keep active within your limits; gentle exercise such as walking helps fatigue
- Ask for help at home from family, carers or community services during treatment
- Keep a symptom diary to share at follow-up, including fevers, memory changes and skin patches
- Seek support from lymphoma charities and patient groups
11. Frequently asked questions
| Question | Answer |
|---|---|
| Why was it so hard to diagnose? | It does not form lumps and causes symptoms that look like many other illnesses |
| Why did I have biopsies of normal skin? | Lymphoma cells are often hidden in skin vessels even when the skin looks normal |
| Is it curable? | Many people achieve long-lasting remission with modern treatment |
| Will it affect my brain? | It can; that is why treatment includes drugs aimed at the brain |
| Is it inherited? | No |
| Is it related to other lymphomas? | Yes, it is a type of large B-cell lymphoma, the most common lymphoma family |
12. Questions to ask your care team
- Which type of IVLBCL do I have?
- Is my brain or spinal fluid involved?
- What will my treatment plan involve, and how long will it last?
- Will I need high-dose methotrexate or spinal fluid treatment?
- What side effects should I report straight away?
- What happens if the lymphoma comes back?
Resources
- Breakell, T. et al. (2022) ‘Intravascular large B-cell lymphoma: a review with a focus on the prognostic value of skin involvement’, Current Oncology, 29(5), pp. 2909-2919.
- Davis, J.W. et al. (2022) ‘Intravascular large B-cell lymphoma’, Archives of Pathology and Laboratory Medicine, 146(9), pp. 1160-1167.
- Ponzoni, M., Campo, E. and Nakamura, S. (2018) ‘Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks’, Blood, 132(15), pp. 1561-1567.
- Shimada, K. and Kiyoi, H. (2021) ‘Current progress and future perspectives of research on intravascular large B-cell lymphoma’, Cancer Science, 112(10), pp. 3953-3961.
- Shimada, K. et al. (2020) ‘Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial’, Lancet Oncology, 21(4), pp. 593-602.
- Shimada, K. et al. (2025) ‘Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trial’, EClinicalMedicine, 80, 103078.
- National Cancer Institute (2026) Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/aggressive-b-cell-lymphoma-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.